LexisNexis® Legal Newsroom
2nd Circuit Reject Overpromotion Exception To Learned Intermediary In Zyprexa Case

NEW YORK - (Mealey's) A Second Circuit U.S. Court of Appeals panel on July 16 ruled that a Zyprexa multidistrict litigation plaintiff failed to show that alleged overpromotion of the atypical antipsychotic drug by manufacturer Eli Lilly and Co. misled the plaintiff's doctor into prescribing the...

2nd Circuit Affirms Injunction Against Lawyer Who Disclosed Zyprexa MDL Documents

NEW YORK - (Mealey's) The Zyprexa multidistrict litigation court properly enjoined an Alaska attorney and mental health advocate from obtaining and disseminating confidential discovery documents produced by Eli Lilly and Co., a panel of the Second Circuit U.S. Court of Appeals ruled Aug. 12 ( Eli...

Burg Simpson Leads National Litigation Against DePuy Orthopaedics

DENVER - Burg Simpson Eldredge Hersh & Jardine P.C., one of the nation's leading plaintiff litigation law firms, has announced that shareholder Seth. A. Katz has been appointed by Judge David A. Katz to serve as a member of the Plaintiffs' Steering Committee in the multidistrict litigation...

AstraZeneca Pays States $68.5M For Off-Label Marketing Of Seroquel Antipsychotic

TRENTON, N.J. - (Mealey's) AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. on March 10 agreed to pay $68.5 million to 37 states and the District of Columbia to resolve allegations in a New Jersey state court lawsuit that it marketed its atypical antipsychotic drug Seroquel for off-label uses...

6 Third-Party Payers Settle Zyprexa Claims For $4.5Million After Class Vacated

BROOKLYN, N.Y. - (Mealey's) The Zyprexa multidistrict litigation judge on Jan. 12 approved a $4.5 million settlement between Eli Lilly and Co. and six third-party payers who had their Racketeer Influence and Corrupt Organizations Act (RICO) class action vacated and who couldn't find any other...

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the risk of diabetes but that the atypical antipsychotic...